BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that PROFIT
Magazine has ranked BioSyent as one of Canada's Fastest-Growing Companies in the
just released 2013 rankings. Published in the Summer issue of PROFIT Magazine
and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their
revenue growth over five years. Based upon a five year revenue (2007-2012)
growth rate of 355%, BioSyent ranked #183 on the PROFIT 500 list.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada.


At the date of this press release the Company had 13,571,195 shares issued and
outstanding.


About PROFIT Magazine and PROFITguide.com

PROFIT: Your Guide to Business Success is Canada's preeminent publication
dedicated to the management issues and opportunities facing small and mid-sized
businesses. For 31 years, Canadian entrepreneurs and senior managers across a
vast array of economic sectors have remained loyal to PROFIT because it's a
timely and reliable source of actionable information that helps them achieve
business success and get the recognition they deserve for generating positive
economic and social change. Visit PROFIT online at PROFITguide.com.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Biosyent Charts.
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Biosyent Charts.